Anagrelide Retard in Essential Thrombocythemia

Clinical trial NCT02076815 · COMPLETED

Trial details

NCT number: NCT02076815
Sponsor: AOP Orphan Pharmaceuticals AG
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Essential Thrombocythemia

Start date: 2014-02-01
Primary completion: 2015-02-01
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.